RAiD 10.26259/904420a2

Reliability of AI scoring for personalised melanoma immunotherapy

Dates

Descriptions

Organisations

Alternate Identifier

No Entries

Related RAiDs

No Entries

Subjects

Raw Data

{
  "metadata": {
    "created": 1723100673,
    "updated": 1742955860
  },
  "identifier": {
    "id": "http://raid.local/10.26259/904420a2",
    "schemaUri": "https://raid.org/",
    "registrationAgency": {
      "id": "https://ror.org/038sjwq14",
      "schemaUri": "https://ror.org/"
    },
    "owner": {
      "id": "https://ror.org/02stey378",
      "schemaUri": "https://ror.org/",
      "servicePoint": 20000003
    },
    "raidAgencyUrl": "https://prod.static.raid.org.au/10.26259/904420a2",
    "license": "Creative Commons CC-0",
    "version": 2
  },
  "title": [
    {
      "text": "Reliability of AI scoring for personalised melanoma immunotherapy",
      "type": {
        "id": "https://vocabulary.raid.org/title.type.schema/5",
        "schemaUri": "https://vocabulary.raid.org/title.type.schema/376"
      },
      "startDate": "2023-01-31",
      "language": {
        "id": "eng",
        "schemaUri": "https://www.iso.org/standard/74575.html"
      }
    }
  ],
  "date": {
    "startDate": "2023-01-31",
    "endDate": "2025-02-28"
  },
  "description": [
    {
      "text": "Despite advances in cancer treatments and increased survival of advanced melanoma patients, most patients with advanced melanoma will still die when treated with routine immunotherapies due to immune evasive mechanisms[1]. The personalised immunotherapy program will, instead, ensure each patient’s cancer is screened for genetic and immune profiles to identify patients unlikely to benefit from standard therapies. These patients will then be assigned a novel clinical trial agent most likely to cure them based on the presence of the drug targets in the patient's tumour. It is anticipated that selecting treatments for patients, based on the presence of specific drug targets in the patient’s cancer, will improve cancer outcomes and increase the survival of people with cancer. \n\nThis project aims to optimise the multiplex immunohistochemistry staining panel that can be used to rapidly identify the profile of immune checkpoint targets in melanoma biopsies. Further, the project aims to elucidate the accuracy of the artificial intelligence (AI) program to correctly identity fluorescent threshold for immune marker positivity. \n\nThis project will accurately and cost effectively fast track patient assessment for immunotherapy treatments; thereby rapidly matching patients with effective therapies to increase the overall cure rate of advanced cancers.",
      "type": {
        "id": "https://vocabulary.raid.org/description.type.schema/318",
        "schemaUri": "https://vocabulary.raid.org/description.type.schema/320"
      },
      "language": {
        "id": "eng",
        "schemaUri": "https://www.iso.org/standard/74575.html"
      }
    }
  ],
  "access": {
    "type": {
      "id": "https://vocabularies.coar-repositories.org/access_rights/c_abf2/",
      "schemaUri": "https://vocabularies.coar-repositories.org/access_rights/"
    },
    "statement": {
      "text": "Access statement example text...",
      "language": {
        "id": "eng",
        "schemaUri": "https://www.iso.org/standard/74575.html"
      }
    },
    "embargoExpiry": "2025-08-08"
  },
  "alternateUrl": [],
  "contributor": [
    {
      "id": "https://orcid.org/0000-0002-6270-1203",
      "schemaUri": "https://orcid.org/",
      "status": "UNAUTHENTICATED",
      "uuid": "c436daee-5f8f-4fef-ba27-305ad24718f5",
      "position": [
        {
          "schemaUri": "https://vocabulary.raid.org/contributor.position.schema/305",
          "id": "https://vocabulary.raid.org/contributor.position.schema/308",
          "startDate": "2023-01-31"
        }
      ],
      "role": [
        {
          "schemaUri": "https://credit.niso.org/",
          "id": "https://credit.niso.org/contributor-roles/conceptualization/"
        }
      ],
      "leader": true,
      "contact": true
    },
    {
      "id": "https://orcid.org/0009-0006-7597-4813",
      "schemaUri": "https://orcid.org/",
      "status": "UNAUTHENTICATED",
      "uuid": "aa353b62-4e5d-4092-933b-7d0fbb13b93c",
      "position": [
        {
          "schemaUri": "https://vocabulary.raid.org/contributor.position.schema/305",
          "id": "https://vocabulary.raid.org/contributor.position.schema/308",
          "startDate": "2023-01-31"
        }
      ],
      "role": [
        {
          "schemaUri": "https://credit.niso.org/",
          "id": "https://credit.niso.org/contributor-roles/supervision/"
        }
      ],
      "leader": false,
      "contact": false
    }
  ],
  "organisation": [
    {
      "id": "https://ror.org/02stey378",
      "schemaUri": "https://ror.org/",
      "role": [
        {
          "schemaUri": "https://vocabulary.raid.org/organisation.role.schema/359",
          "id": "https://vocabulary.raid.org/organisation.role.schema/182",
          "startDate": "2023-01-31"
        }
      ]
    }
  ],
  "subject": [
    {
      "id": "https://linked.data.gov.au/def/anzsrc-for/2020/3202",
      "schemaUri": "https://vocabs.ardc.edu.au/viewById/316",
      "keyword": [
        {
          "text": "Subject keyword example text...",
          "language": {
            "id": "eng",
            "schemaUri": "https://www.iso.org/standard/74575.html"
          }
        }
      ]
    }
  ],
  "relatedRaid": [],
  "relatedObject": [],
  "alternateIdentifier": [],
  "spatialCoverage": []
}